Skip to content

Our Purpose

An Ethical Imperative

Effective pain management for laboratory animals is an essential need in today’s research institutions.

Leading laboratory associations, including the Office of Laboratory Animal Welfare (OLAW), increasingly recognize the ethical and scientific importance of using the highest-quality analgesics available to protect the welfare of laboratory animals and limit variability in research results.

Fidelis Pharmaceuticals is a  commercial stage company with a product platform focused on fulfilling unmet needs for pharmaceutical-grade pain management for laboratory animals and additional species:

Important Safety Information

For Rats and Mice:
Only administer Ethiqa XR by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use on mice or rats with pre-existing respiratory deficiencies. Do not keep rats on wood chip-type bedding after administration of Ethiqa XR. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression.

For Humans:
Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids. Protective clothing is recommended to avoid direct contact with human skin or mucus membranes which could result in absorption of buprenorphine and adverse reactions. Not for use in humans.

For more information, consult the Prescribing Information including the Boxed Warning.

WARNING: ABUSE POTENTIAL and LIFE-THREATENING RESPIRATORY DEPRESSION and ACCIDENTAL EXPOSURE

Abuse Potential

Ethiqa XR contains buprenorphine, a high-concentration (1.3 mg/mL) opioid agonist and Schedule III controlled substance with an abuse potential similar to other Schedule III opioids. The high concentration may be a particular target for human abuse. Buprenorphine has opioid properties that in humans may lead to dependence of the morphine type. Abuse of buprenorphine may lead to low or moderate physical dependence or high psychological dependence. The risk of abuse by humans should be considered when storing, administering, and disposing of Ethiqa XR. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (suicidal depression). Because of human safety risks, this drug should be used only with veterinary supervision.

Do not dispense Ethiqa XR.

Life-Threatening Respiratory Depression

The concentration of buprenorphine in Ethiqa XR is 1.3 mg/mL. Respiratory depression, including fatal cases, may occur with abuse of Ethiqa XR. Ethiqa XR has additive CNS depressant effects when used with alcohol, other opioids, or illicit drugs that cause central nervous system depression. Because of the potential for adverse reactions associated with accidental injection, Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids.

Our Promise

Fidelis gives you the assurance of a high standard in the quality of our products, our materials, and our methods.

Our Lead Product, Already Widely Used by Researchers, Offers:

FDA-indexed extended-release buprenorphine. Made in a cGMP-regulated facility.

Pharmaceutical grade. Indexed by FDA.

ETHIQA XR

Connect with us

Fidelis is actively seeking new partnerships and product opportunities. If would like to get more information or would like to discuss investment, partnership, or new product development opportunities with the Fidelis leadership team, please contact us below. Thank you for your interest.